Companies

1717 LSV empowers scientists and investors to transform early stage radiopharmaceutical projects into attractive assets for licensing partners in industry. By introducing early stage investors to promising new projects, 1717 LSV seeks to enable novel radiopharmaceutical therapies to traverse the early stages of manufacturing and clinical development.

Management: Anna Steeger, Dr Hakim Bouterfa, Dr Jens Kaufmann

+49 30 9489 3221
info@1717LSV.com
1717LSV.com
located at: A7

Services for Biotech & Pharma

The Eckert & Ziegler Group is one of the world's largest providers of isotope technology for medical, scientific and industrial use. The core businesses of the Group are cancer therapy, industrial radiometry and nuclear-medical imaging.

Management: Dr. Harald Hasselmann

+49 30 9410840
info@ezag.de
www.ezag.de
located at: A7

Medical Technology, Services for Biotech & Pharma

Management: Jens Reinwardt

+49 30 9489 2293
vorstand@gesundheit-akademie.de
Akademie der Gesundheit Berlin-Brandenburg e.V.
located at: D79

Services for Biotech & Pharma

Die wissenschaftlich fundierte Entwicklung von Mikropartikeln, die einen pharmazeutischen Wirkstoff beinhalten, Beratung von Unternehmen bei der Entwicklung von Mikropartikeln und bei der Maßstabsvergrößerung für die kommerzielle Herstellung.

Management: Dr. Heiko Seemann (CEO)

+49 30 9489 2480
info@navitapharm.de
www.navitapharm.de
located at: D80

Drug Delivery

Management: Dr. Timo Hillebrand

+49 30 9489 3380
info.innu@ist-ag.com
IST Innuscreen GmbH
located at: B55

Molecular Diagnostics

aokin AG is specialized in innovative immunochemical analysis systems.
Our main focus is in the development and sale of reliable methods for quantitative trace analysis using rapid kinetic assay technology.

aokin systems are exceptionally fast and precise. Results are determined within a few minutes.They reduce both the time and expense required for analysis, and are more economical than conventional methodologies
(ELISA, HPLC).

A core focus of the company is the detection and quantification of toxins in food. Under the direction of the company’s founder, Dr. Ursula Dahmen-Levison, a team of experienced German and American scientists are steadily working on continual advancement of aokin methodology. The aokin system is also available for antibody screening and medical in vitro diagnostics.

Management: Dr. Ursula Dahmen-Levison (CEO)

+49 30 9489 2160
info@aokin.com
AOKIN AG
located at: D85

Molecular Diagnostics, Services for Biotech & Pharma

ART-CHEM GmbH in Berlin-Buch - since 15 years - offers a perfect choice of unique organic compounds for bioscreening. In our partner laboratory were synthesized new compounds for High Throughput Screening and Building Blocks Library for Combinatorial Chemistry. The application of the NMR and LC-MASS analysis methods guarantees high quality control of all the samples. The company also provides top level custom synthesis and scientific projects.

Management: Dr. Alexej Uschmajew

+49 30 9489 2180
art-chem@campus-berlin-buch.de
ART-CHEM GmbH
located at: B55

Molecular Diagnostics, Services for Biotech & Pharma

We founded ASC Oncology to address one of the most pressing challenges in modern oncology: providing patients with the right therapy at the right time.

Chemotherapy fails for around half of the world’s cancer patients. Therapy-resistant tumors are responsible for the majority of cancer deaths and burden healthcare systems considerably.

With approximately 20 million new cancer cases worldwide every year, the successful treatment of cancer patients through individualised therapies has enormous potential. ASC Oncology seeks to identify the best possible chemotherapy for each patient and rule out those which will probably prove to be ineffective.

Management: Dr. Christian Regenbrecht

+49 30 9489 4422
hello@asc-oncology.com
ASC Oncology GmbH
located at: D79

Molecular Diagnostics

Applications: career@ascenion.de

Management: Dr. Christian Stein, Contact person in Berlin-Buch: Dr. Michael Karle; Contact person in Berlin-Buch: Dr. Elisabeth von Weizsäcker

+49 30 9489 3004
berlin@ascenion.de
Ascenion GmbH
located at: D85

Services for Biotech & Pharma

Berlin Cures was first to follow up on the scientific finding that there are a large number of diseases associated with pathological functional autoantibodies directed against G protein-coupled receptors. Heart failure and Long Covid belong to this group of diseases. BC 007 can neutralize these autoantibodies and this is why Berlin Cures has developed a product based on scientific knowledge that may help many suffering patients.  

Management: Dr. Johannes Müller, Dr. Peter Göttel

+49 30 9489 2060
jmueller@berlincures.de
Berlin Cures GmbH
located at: D79

Drug Development

BIOSYNTAN GmbH was founded in 1997 as a scientific service company, focused on custom synthesis of peptides. A rising interest of our customers in modified peptides has prompted us to develop new methods for the manufacturing of such compounds. As one of the leading specialists in the synthesis of linear and cyclic peptides with unusual residues and a multitude of modifications we can offer you an extensive range of services today.

Our core area is the manufacturing of fluorescently labeled peptides for assay development and the synthesis of post-translationally modified peptides.

Management: Dr. Stephan Pritz, General manager, Jacqueline Dalski, General manager

+49 (0)30 - 94 89 34 98
biosyntan@biosyntan.de
Biosyntan Gesellschaft für bioorganische Synthese mbH
located at: D85

Services for Biotech & Pharma

The BioTeZ Berlin-Buch GmbH is a Biotechnology company founded in 1992. BioTeZ is partner of research institutions, the pharmaceutical industry and laboratory diagnostics. Our sister company Steffens-Biotec, Ebringen (ISO 13485) is specialised in manufacturing CE in-vitro diagnostics.

Management: Uwe Ahnert

+49 30 9489 2130
info@biotez.de
BioTeZ Berlin-Buch GmbH
located at: D72

Molecular Diagnostics, Services for Biotech & Pharma

Management: Herr Thomas Brotmann

030 94414576 / Funk. 0171-4228092
info@broma-elektro.de
Broma-Elektroanlagen GmbH
located at: B55

Services

Management: Jens Dörflinger

+49 30 9489 2300
cafe-max@campus-berlin-buch.de
Café Max
located at: A8

Services

Campus Berlin-Buch GmbH is developing the international campus together with the research institutions as an innovative and sustainable science and technology location. With its reputation, the campus is the heart of Berlin-Buch, a location of future innovation.

The BiotechPark Berlin-Buch is most important pillar of the company. Founded in 1995, it is an integral part of the campus. Assisting and supporting the settlement of biotech companies from start-ups to mature enterprises – comprise the key tasks of Campus Berlin-Buch GmbH. It is currently building the new BerlinBioCube incubator center.

Management: Dr. Christina Quensel, Dr. Ulrich Scheller

+49 30 9489 2511
info@campusberlinbuch.de
Campus Berlin-Buch GmbH
located at: D85

Services for Biotech & Pharma

celares is a CDMO focused on the development and manufacturing of polymer based drug delivery excipients and bioconjugate drugs.

Management: Dr. Frank Leenders, Dr. Ralf Krähmer, Dipl. Kaufmann Günther Pätz

+49 30 9489 2350
ber.office@biosynth.com
Biosynth GmbH
located at: D80

Drug Delivery, Services for Biotech & Pharma

CELLphenomics delivers innovative PD3D® models to oncology drug development, accelerating your journey from the laboratory bench to the clinic – decreasing timelines, lowering costs, and ultimately saving patient lives.

Management: Quirin Graf Adelmann v. A. & Dr. Christian Regenbrecht

+49 30 9489 4422
quirin.adelmann@cellphenomics.com
www.cellphenomics.com
located at: D79

Drug Development, Services for Biotech & Pharma

Management: Annette Köhler, Tel: +49 (0)30/ 9489 2250. Fax: + 49 (0)30 / 9489 2251, Mobile: 0174/ 99 35 111, E-Mail: annette.koehler@circle-institute.com

+49 (0)30 9489 2250
info@circle-institute.com
Circle institute GmbH
located at: D85

Services for Biotech & Pharma

Management: Dr. Steffen Mergemeier

+49 30 9489 3500
info@congen.de
www.congen.de
located at: B55

Molecular Diagnostics

Management: Marion Bimmler, Bernd Lemke

+49 30 9489 2222
bimmler@aak-diagnostik.de
www.aak-diagnostik.de
located at: B55

Molecular Diagnostics

Eckert & Ziegler BEBIG is an expert in the field of brachytherapy and manufactures small radioactive implants, so-called "seeds", which are mainly used in LDR brachytherapy for the treatment of localised prostate cancer. The company is he only global provider of Ru-106 Eye Applicators for the treatment of ocular melanomas and retinoblastomas.

Management: Dr. Harald Hasselmann, Dr. Dirk W. Becker

+49 30 9410840
info@bebig.de
www.ezag.de
located at: A7

Medical Technology

Small organic molecules, such as fluorophores, haptens, and other modifiers of biomolecules, are vital tools for research in the life sciences.

emp BIOTECH offers a wide variety of innovative products and services for labeling, purification and modification techniques, including fine chemicals, kits for labeling and purification, coupling reagents, and chemical modification services.

Management: Dr. Derek Levison, Dr. Uwe Möller

+49 30 9489 2201
info@empbiotech.com
EMP Biotech GmbH
located at: D85

Molecular Diagnostics, Services for Biotech & Pharma

engine - the biomarker company is your reliable partner for discovering your biomarker for diagnostics and therapy. With our protein arrays we screen your sample for interactions with > 10,000 human antigens. In this way, you will obtain your results much faster than with standard methods and benefit from a maximum outcome. Our protein arrays are part of more than 100 publications to date and have been developed on the basis of more than 15 years of intensive research.

Management: Prof. Dr. Jörg-M. Hollidt

info@proteinarrays.bio
in.vent Diagnostica GmbH
located at: D79

Molecular Diagnostics

Based on a more than 20 years experience, EPO offers customized and comprehensive service for the preclinical development of new cancer drugs.

Management: Dr. Jens Hoffmann (CEO)

+49 30 9489 4440
jens.hoffmann@epo-berlin.com
EPO Experimentelle Pharmakologie & Onkologie Berlin-Buch GmbH
located at: D82

Drug Development, Services for Biotech & Pharma

Management: Dr. Wolfgang Fecke (Director General)

030 9489 2420
office@eu-openscreen.eu
www.eu-openscreen.eu
located at: C87

Services for Biotech & Pharma

Monday - Friday 10:00 am until 6:00 pm
Saturday 11:00 am until 3:00 pm
Phone: (030) 9416635

Management: Jan Römhild

(030) 9416635
www.fahrradhofbuch.de
located at: A12

Services

Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies. Glycotope antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GlycoTargets). Glycotope has to date discovered in excess of 150 GlycoTargets with antibodies against several of these targets currently under development.

Based on their superior tumor-specificity, Glycotope antibodies are suitable for development in an array of different modes of action including naked antibodies, bispecifics, antibody-drug-conjugates, cellular therapies or fusion-proteins.

Currently six clinical and pre-clinical programs based on this technology are under development by Glycotope or its licensing partners.

Management: Henner Kollenberg (Managing Director)

+49 30 9489 2600
contact@glycotope.com
Glycotope GmbH
located at: D85

Drug Development, Services for Biotech & Pharma

Management: Contact person: Christopher Grube

+49 (30) 49009-148
c.grube@grg.de
www.grg.de
located at: B55

Services

HealthTwiSt provides targeted Data Science services. This includes various steps of data generation and analysis in research, such as sample size calculations prior to experiments or trials, data management solutions with web-based Electronic Case Report Forms (eCRF) for data protection during and after studies, as well as statistical analyses with informative figures and tables, hypothesis testing, data mining, and machine learning. We are strongly devoted to the principles of reproducible research:  Every step of the analysis from data import over transformations up to publication-ready tables and figures is fully traceable, based on R scripts.

Management: CEO: Dr. Andreas Busjahn

030 9489 3235
info@healthtwist.de
HealthTwiSt GmbH
located at: D85

Services for Biotech & Pharma

Management: Dr. Michael Hermes

+49 30 9489 4807
michael.hermes@aol.com
located at: B55

Services for Biotech & Pharma

Invitek Diagnostics is a global provider of molecular diagnostics products that cover the full spectrum of workflows, from sample to result. Get ready to simplify your workflows and enjoy streamlined processes.

Management: Thomas Matthes

+49 30 9489 2908
info@invitek.com
Invitek Diagnostics Germany (Invitek Molecular GmbH)
located at: D85

Molecular Diagnostics, Services for Biotech & Pharma

Management: Matthias Fuchs

+49 30 9489 3179
located at: A15

Services

Management: Dr. Michael Rothe

+49 30 9489 3210
michael.rothe@lipidomix.de
www.lipidomix.de
located at: B55

Services for Biotech & Pharma

Management: Dr. Andreas Vente

+49 30 9489 4050
info@merlionpharma.de
www.merlionpharma.com
located at: D85

Drug Development

MRI.TOOLS’s main focus is the development, sales and services of innovative hardware and novel technology for magnetic resonance imaging (MRI). Our product portfolio encompasses enabling radiofrequency coils tailored for a broad range of biomedical applications from head to toe. We also offer devices for reliable cardiac gating of imaging plus accessories that will make your daily life more comfortable. MRI.TOOLS is also very proud to offer services such as electromagnetic field simulations, testing and validation of medical devices for clinical research.

Management: Prof. Thoralf Niendorf

+49 30 9406 4513
info@mritools.de
www.mritools.de
located at: B55

Medical Technology

Management: Dr. Michael Möller,Contact person in Berlin-Buch: Marco Cali, Contact person in Berlin-Buch: Matthias Wilke

+49 151 42638851
marco.cali@nikon.de
www.nikoninstruments.com/en_DE
located at: B55

Medical Technology

Ariceum Therapeutics is a private clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.

Management: Contact: Dennis Mewis

+49 30 9489 3360
info@ariceum-therapeutics.com
Ariceum Therapeutics GmbH
located at: D79

Drug Development, Molecular Diagnostics

OMEICOS Therapeutics is focused on developing therapies that have the potential for a significant impact on cardiovascular, inflammatory and mitochondrial diseases with high unmet need. Our pipeline is based on our proprietary approach to target one of nature’s most important cell-protective pathways and industry-leading knowledge of omega-3 fatty acid metabolism and biology.

Management: Dr. Robert Fischer

+49 (0)30 9489 4810
info@omeicos.com
OMEICOS Therapeutics GmbH
located at: D79

Drug Development

PentixaPharm is committed to developing the innovative theranostic pair PentixaFor and PentixaTher. PentixaFor and PentixaTher are two-small peptide-based radiopharmaceuticals which specifically target the CXCR4-receptor expressed in most fast progressing diseases such as hematological and solid cancers as well as cardiovascular malignancies.

Management: Anne Lobach / Finance and Administration Manager

030 / 94 89 32 20
anne.lobach@pentixapharm.com
PentixaPharm AG
located at: D85

Molecular Diagnostics, Medical Technology

Management: Prof. Georg Winterer

+49 30 9489 2490
georg.winterer@charite.de
https://pi-pharmaimage.com/
located at: D85

Services for Biotech & Pharma

Management: Dr. Ingo Fritz

+49 30 9489 2165
i.fritz@roboklon.de
www.roboklon.de
located at: B55

Molecular Diagnostics, Services for Biotech & Pharma

Management: Antje Mika, Contact person on site: Ms. Fischer-Swierczynski

+4930 9489 3546
campussterne@sehstern-ev.de
www.sehstern-ev.de
located at: B61

Services

At Silence, our vision is to transform peoples’ lives around the world by silencing diseases through our precision engineered medicines and driving positive change for the communities around us. As pioneers in the design and development of siRNAs (short interfering RNAs), we are advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. We are proud to be a global and diverse company from our locations to our culture and expertise spanning from drug discovery to clinical development and commercialization.

Management: Craig Tooman

+49 30 9489 2800
info@silence-therapeutics.com
www.silence-therapeutics.com
located at: D80

Drug Development, Drug Delivery

Management: Silke Langmacker

+49 30 46 000 80
info@langmacker.de
www.langmacker.de
located at: D85

Services for Biotech & Pharma, Services

T-knife is a clinical-stage Biotech company developing T cell receptors (TCRs) for T cell therapy of cancer which are derived from T-knife’s proprietary Humanized TCR Mice platform.

Management: Dr. Elisa Kieback

+49 30 94892432
info@t-knife.com
T-Knife GmbH
located at: D85

Drug Development

Management: Contact: Ms Bergmann and Mr Hynitzsch

+49 30 949 5736
mensa@campus-berlin-buch.de
Widynski & Roick GmbH
located at: A14

Services

+49 (0)30 611 07 611
mail@rock-paper.berlin
http://rock-paper.berlin/
located at: A14

Services

Cambrium's mission is to trigger the next wave of material innovation by harnessing nature’s protein building blocks. Our platform combines protein engineering, machine learning and lab automation to create high-performance materials at scale. Our first product is a vegan collagen for the cosmetic industry. We look forward to meeting you all on the Campus and would love to dive into any conversations about proteins, the bioeconomy, lab automation and/or data mining.  

info@cambrium.bio
Cambrium GmbH
located at: D80

Medical Technology

Molecular Devices is one of the world’s leading providers of cellular imaging instruments and microplate readers for life science research, pharmaceutical and biotherapeutic development, with over 30 years’ experience and 140,000+ placements in labs around the world. On the Berlin-Buch campus, we’re delighted to give you access to our unique ImageXpress family of automated microscopy and high-content cellular imaging systems, which enable diverse applications from basic cell counting to advanced high-throughput 3D analysis. Please contact our team for more details.

030 9489 3230
https://de.moleculardevices.com/
located at: D79

Molecular Diagnostics

Management: Andreas Hurny

info@bctlaboratory.de
Barbara Cell and Tissue Laboratory
located at: D80

Medical Technology

PRAMOMOLECULAR, a spin-off of the TU Berlin, is developing drug candidates to silence oncoproteins in the lung and pancreas. To do this, we covalently couple lipid residues to short interfering RNAs ("siRNAs") via defined chemical bonds. As soon as these self-delivering siRNAs bind to a complementary messenger RNA in their target cell, the mRNA is degraded by a cell's own enzyme complex. This means that the blueprint for a protein is missing. In this way, pathogenic proteins can be downregulated ("gene silencing").

siRNAs are sensitive and have difficulty reaching their target cell in the body. For this purpose, they have so far mainly been packaged in nanoparticles. However, these primarily reach liver cells. PRAMOs self-delivering siRNAs can downregulate pathogenic proteins in lung and pancreas cells in vivo. In this way, we address KRAS oncoproteins, the most important cancer drivers in lung and pancreatic carcinoma.

Management: Merle Fuchs, PhD CET, Project Leader, Business Development, Financing

0171 4542042
fuchs@pramomolecular.com
PRAMOMOLECULAR GmbH
located at: D79

Drug Development, Drug Delivery

At ACARYON, customers do find the scientific innovation and expertise necessary for any purposes along the path of product development.

Customers can rely on our experience in target identification, pre-clinical and clinical development, establishment and optimization of fermentation and production process as well as regulatory aspects. Combining a unique technology platform and our expertise in microbial cabohydrates for the development of indication specific next generation microbiome products.    

Management: Dr. Philippe Ulsemer, Managing Director

+49 (0)1512 4041809
info@acaryon.com
ACARYON GmbH
located at: D79

Services for Biotech & Pharma

Eckert & Ziegler Radiopharma GmbH is a leading expert in the development, production and distribution of radionuclides and radiopharmaceuticals for nuclear medicine and other fields of activity.

Management: Dr. Andreas Eckert, Dr. Lutz Helmke

+49 30 9410840
info.radiopharma@ezag.de
Eckert & Ziegler Radiopharma GmbH
located at: A7

Medical Technology, Services for Biotech & Pharma

FyoniBio is a newly formed contract development and clinical lab company continuing the service business of Glycotope on the biotech campus Berlin Buch. FyoniBio is offering 20 years of experience in developing biopharmaceuticals to customers. FyoniBio is an ISO 9001 certified company and operates in part under GCLP. Comprehensive one-stop shop services, from clone development to RCB for CHO and GEX cell lines, process development ready to transfer to the GMP facility of your choice, cutting edge know-how in glycobiology (analytics and cell biology), bioassay development for a wide range of proteins. Excellent know-how in clinical PK, biomarker and immunogenicity analysis of clinical samples under good clinical and laboratory practice (GCLP).

Management: Dr. Lars Stöckl, Managing Director, Dr. Hans Baumeister, Managing Director, Dr. Xiao Shen, Managing Director

+49 (0) 30 9489 2500
contact@fyonibio.com
FyoniBio GmbH
located at: D85

Services for Biotech & Pharma

Management: Prof. Thomas Walther

twalther@xitratherapeutics.com
Xitra Therapeutics GmbH
located at: D79

Drug Development

Here to deliver innovative technologies that advance insight into cell biology

We are a young and dynamically growing spin-out company from Oxford, UK. The company was founded in summer 2016 by scientists from the Department of Engineering Science and the Sir William Dunn School of Pathology, University of Oxford, UK.
We take pride in our mission to develop technologies that advance discovery into cell biology.

Since its inception, iotaSciences has been committed to offer cell researchers highly user-friendly, reliable and powerful technologies with unique capabilities that greatly simplify and facilitate breakthrough advances in cell biology.

We believe in treating clients, customers and collaborators as partners whose invaluable feedback steers technology development and progression.

ntelugu@iotasciences.com; afeuerborn@iotasciences.com
IOTA SCIENCES GmbH
located at: D79

Services for Biotech & Pharma

Management: Gernot Jehle

+49 30 2900 6110
info@schallware.de
Schallware GmbH
located at: B55

Medical Technology

BEBIG Medical GmbH (“BEBIG Medical”) is a global provider of high quality radiation therapy products for cancer treatment headquartered in Berlin, Germany. Preceded by the high dose brachytherapy business unit of Eckert & Ziegler AG, BEBIG Medical has a heritage of more than 40 years’ experience in brachytherapy field and continues to provide affordable healthcare with proven clinical outcomes via strong and viable technology. BEBIG Medical’s US subsidiary, Mick Radio-Nuclear Instruments, Inc., is also known internationally for its manufacturing expertise in the field of applicators and accessories to advance brachytherapy. With a team of professionals and offices in Europe, United States and Asia, the company is empowered to serve customers in more than 70 countries and regions together with a worldwide distribution network.

+49 30 9487888-10
sales@bebigmedical.com
BEBIG Medical GmbH
located at: D23

Medical Technology

PROSION developed a first-in-class approach to address so far undruggable pharmaceutical targets that are linked with various hard-to-treat diseases through a disruptive platform of chemical building blocks called ProMs.

ProMs can in fact be combined to form the world’s first small molecule drugs for a very abundant class of “undruggables”, namely proline-rich-motif (PRM) binding targets.

These targets are known to play key-roles in a multitude of pathologies, e.g. cancer, diabetes, Alzheimer’s, cardiovascular diseases, immune-meditated disorders, etc.

The potential of the ProM-platform has already been validated in a first POC targeting a particularly difficult oncological PRM-binding target.

Management: Dr. Slim Chiha and Mutlu Yönel

+49 1578 8517161
info@prosion.eu
PROSION GmbH
located at: C81

Drug Development

0178 542 0946
carla.glassl@ucaneo.com
Ucaneo Biotech GmbH
located at: B55

Services for Biotech & Pharma

Trade in diagnostics and therapeutic products, especially for early stages, in vitro diagnostics and stem cell therapy.

Management: Xiushan Yin

xiushanyin@rocrockbio.com
located at: B55

Drug Development, Services for Biotech & Pharma

"Preclinical Identification of Mechanism of Action and Target Identification for T03-04."

The project explores the mode of action as well as the mechanism of action of the new, patent-protected chemical entities Treamid03 and Treamid04.

The molecules will be investigated for their therapeutic potential in the treatment of inflammatory respiratory diseases.

info@treamid.com
Treamid Therapeutics GmbH
located at: D80

Drug Development

Myelo Therapeutics GmbH develops innovative treatments in areas of high unmet medical needs.

Management: Dirk Pleimes, MD

+49 (0)30 6890 8696
info@myelotherapeutics.com
Myelo Therapeutics GmbH
located at: D80

Drug Development

Curofin Pharma is developing and commercializing antibiotics to treat bacterial infections in humans. Of highest priority to Curofin are thereby the safe and effective treatment of patients with its medications, making meaningful differences in their lives while also reducing the economic and social burden of infectious diseases to society.

located at: D85

Drug Development

MyoPax's mission is to deliver effective muscle regeneration therapies that restore muscle function.

Management: Verena Schöwel-Wolf, MD, MBA

info@myopax.eu
MyoPax GmbH
located at: B51

Drug Development, Molecular Diagnostics

At Absea, our mission is to empower protein science by delivering protein products with unmatched quality, characterization depth, and manufacturing speed. We have built the world's largest high-throughput protein expression platform and soluble human protein repository, and are developing monoclonal antibodies to target the entire proteome. As a driver of innovation, we are augmenting our expertise in protein biotechnology with state-of-the-art AI and bioinformatics tools. With this unique skill set, we strive to become a long-term partner for the world's leading labs, companies and service providers in proteomics, in vitro diagnostics, biopharmaceutical, and life science research.

Management: Contact: Dr. Philip Lössl

philip.loessl@absea.bio
Absea Biotechnology GmbH
located at: D85

Molecular Diagnostics, Services for Biotech & Pharma

0172 2959472
info@ichortec.com
ICHORtec GmbH
located at: B55

Molecular Diagnostics